Simeprevir and PR was significantly superior to placebo and PR ; rates of sustained virologic response @ weeks after planned end of treatment ( SVR@ ) were @ % vs @ % , respectively ( @ % difference ; @ % confidence interval , @-@ @ ; P < @ ) .